Introduction
Materials and methods
Results
Patient characteristics | Number of Patients |
---|---|
Histology | |
Adeno -Ca | 83 |
Squamous Cell Ca | 80 |
Other | 17 |
cT-category | |
T1 | 18 |
T2 | 35 |
T3 | 53 |
T4 | 74 |
cN-category | |
cN2/N3 - positive by EBUS and positive by PET | 102 |
cN2/N3 - negative by EBUS and positive by PET | 30 |
cN2/N3 - positive by EBUS and negative by PET | 7 |
UICC-stage | |
IIIA | 74 |
IIIB | 80 |
IIIC | 26 |
RT-intent | |
Definitive RT/CTx | 114 |
Neoadjuvant RT/CTx | 66 |
Laterality of the primary tumor | |
left-sided | 83 |
right-side | 93 |
bilateral | 4 |
Age | Median and Range |
Median | 62.9 years |
Range | 43.6–84.0 years |
Procedure | Number of assessed LN-stations | LN-stations with positive findings | LN-stations with negative findings |
---|---|---|---|
EBUS-TBNA | 675 | 291 | 384 |
Reported PET-Result | 675 | 377 | 298 |
Coverage of the LN-station by the clinical target volume (CTV) | 675 | 416 | 259 |
Nuclear medicine report positive | Nuclear medicine report negative | Irradiated LN-stations | Not-irradiated LN-stations | |
---|---|---|---|---|
EBUS-TBNA positive | 275 | 16 | 289 | 2 |
EBUS-TBNA negative | 102 | 282 | 127 | 257 |
Irradiated LN-station | 338 | 78 | ||
Not-irradiated LN-station | 39 | 220 | ||
Nuclear medicine report positive and EBUS-negative LN-stations | 64 | 38 | ||
Nuclear medicine report negative and EBUS-positive LN-stations | 15 | 1 | ||
Nuclear medicine report negative and EBUS-negative LN-stations | 63 | 219 |
LN echelon-1 | PET+: | n = 152 | PET-: | n = 17 |
PET+, EBUS+: | n = 144 | PET-, EBUS+: | n = 1 | |
LN echelon-2 | PET+: | n = 170 | PET-: | n = 127 |
PET+, EBUS+: | n = 114 | PET-, EBUS+: | n = 12 | |
LN echelon-3 | PET+: | n = 55 | PET-: | n = 154 |
PET+, EBUS+: | n = 17 | PET-, EBUS+: | n = 3 |